Healthcare shares are generally flat in pre-market trade.
) has initiated a clinical trial to evaluate the combination of the
company's investigational anti-PD-1 immunotherapy, MK-3475, and
) orally administered kinase inhibitor, pazopanib, in advanced
renal cell carcinoma.
Merck and GlaxoSmithKline entered a collaboration to study
MK-3475 with pazopanib and other agents in the GlaxoSmithKline
portfolio in the future.
And, Depomed Inc. (
) has acquired the U.S. rights to non-steroidal anti-inflammatory
drug CAMBIA from Nautilus Neurosciences (
) for $48.7 million. In addition, DEPO may pay NLS up to an
additional $5 million based on the achievement of certain annual
net sales milestones.
DEPO expects the acquisition of CAMBIA to be immediately
accretive and updated its year-end cash guidance to $272
Shares are flat near the stock's 52-week high of $8.85. NLS is
flat at $7.80.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.